Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Clinical trial NCT01804829 · COMPLETED

Trial details

NCT number: NCT01804829
Sponsor: Biotest Pharmaceuticals Corporation
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatitis C Infection Viruses Hepatocellular Carcinoma Hepatitis, Viral, Human Liver Cirrhosis

Start date: 2013-06-01
Primary completion: 2016-02-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.